Welcome to our dedicated page for DarioHealth SEC filings (Ticker: DRIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DarioHealth Corp. filings document the regulatory record of a Nasdaq-listed digital health company with common stock registered under the Exchange Act. Recent 8-K reports cover material agreements, including equity offering arrangements, securities purchase agreements and amendments to credit facilities, along with related capital-structure disclosures involving common stock, preferred stock and pre-funded warrants.
The company’s filings also record governance and charter matters, including amendments to its certificate of incorporation, preferred stock designation changes, annual meeting voting results and board appointments. These disclosures frame DRIO’s formal reporting around financing activity, security-holder rights, corporate governance and material events tied to its digital therapeutics business.
DarioHealth Corp. (DRIO) reports that Lawrence Leisure has retired from its Board of Directors, effective September 2, 2026, for personal reasons. The company states that his decision to retire did not result from any disagreement regarding its operations, policies, or practices. The report is signed by Chief Financial Officer, Treasurer and Secretary Chen Franco‑Yehuda.
DarioHealth Corp. (DRIO) announced that Steven Nelson, its President and Chief Commercial Officer, will cease serving in that role effective September 1, 2026, and his employment will terminate on September 30, 2026 under a Separation Agreement. He will receive earned wages, accrued and unused vacation, continued health insurance coverage through September 30, 2026, and up to three months of COBRA premium reimbursement at $2,600 per month, subject to the agreement’s terms. Outstanding equity awards will remain governed by existing plans and agreements, with any unvested awards expiring upon termination. Nelson will assist with transition matters through December 31, 2026. In parallel, DarioHealth and Nelson entered into a Consulting Agreement, effective October 1, 2026, under which he will provide advisory and consulting services through December 31, 2027, unless ended earlier. As consideration, he will be granted 30,000 shares of restricted common stock, subject to Compensation Committee approval, vesting on the first anniversary of the grant date or earlier upon a Change in Control, with partial accelerated vesting if the consulting relationship is terminated by the company.
DarioHealth Corp. reported for the quarter and six months ended June 30, 2026 that it remains a single-segment digital therapeutics and whole‑person health platform focused on chronic and behavioral conditions. Total assets were $96.6 million, including $6.6 million in cash and cash equivalents and $7.3 million in short‑term deposits, against a long‑term loan of $31.1 million and an Orbimed warrant liability of $15 thousand.
Revenues were $5.2 million and $10.8 million for the three and six months, down 3.6% and 11.2% year over year, mainly from lower pharma‑channel revenue, partly offset by growth in channel partners and direct‑to‑consumer sales. Gross margin improved, supported by lower amortization, lower hosting costs and a $369 thousand IEEPA tariff refund benefit. Operating expenses fell sharply: research and development, sales and marketing, and general and administrative all declined, reflecting post‑merger efficiencies and reduced stock‑based compensation.
The company’s net loss narrowed to $7.9 million for the quarter and $16.2 million year‑to‑date, from $13.0 million and $22.2 million, respectively, aided by lower operating and financial expenses. Operating cash outflow was $12.1 million for the six months. Management notes an accumulated deficit of $468.3 million but cites a July 22, 2026 registered direct offering providing approximately $23.5 million in gross proceeds and believes available funds support operations for at least twelve months from issuance of these statements.
DarioHealth Corp. director Dennis Matheis purchased 14,430 shares of Common Stock at $6.93 per share on July 23, 2026, under a Securities Purchase Agreement dated July 22, 2026. Earlier, on August 12, 2024, 50 shares of his Series B-2 Preferred Stock automatically converted into 965 post–reverse-split common shares, subject to a 19.99% beneficial ownership blocker, and he beneficially owned 28,596 common shares immediately after that conversion.
DarioHealth Corp. is conducting a registered direct offering of 3,454,559 shares of common stock (or common stock equivalents) at $6.80 per share, for aggregate gross proceeds of approximately $23.5 million before fees and expenses. The securities include 2,437,060 shares of common stock and pre-funded warrants to purchase 1,017,499 shares at $6.7999 per warrant.
Board member Dennis Matheis is purchasing 14,430 additional shares at $6.93 per share. The pre-funded warrants are immediately exercisable but have beneficial ownership limits that generally restrict any holder and its affiliates from exceeding 4.99% or 9.99% ownership without advance notice or, in some cases, shareholder approval.
A.G.P./Alliance Global Partners is acting as sole placement agent, earning a 6.0% cash fee on most gross proceeds (1.0% for certain investors) plus up to $60,000 of reimbursed expenses. For 30 days after closing, the company agreed not to issue most new equity or file additional registration statements, while retaining the ability to use its existing at-the-market facility. Net proceeds are intended for working capital, investments, acquisitions, and general corporate purposes.
DarioHealth Corp. is conducting a registered direct offering under its shelf registration, issuing 2,451,490 shares of common stock and pre-funded warrants to purchase 1,017,499 shares. Common stock is priced at $6.80 per share (with 14,430 shares purchased by a director at $6.93), and the pre-funded warrants are priced at $6.7999 with a de minimis exercise price of $0.0001 per share and no expiration date.
The total offering amount is $23,590,899, with placement agent fees of $482,808 and $23,108,091 in proceeds to the company before expenses; DarioHealth estimates net proceeds of approximately $23.6 million for working capital, investments, acquisitions, and general corporate purposes. The deal is on a “reasonable best efforts” basis with no minimum offering amount, so fewer securities may be sold.
The company reports a going concern uncertainty: as of March 31, 2026 it had $20.0 million in cash, cash equivalents and short-term bank deposits versus $9.4 million in current liabilities and does not believe existing cash will fund planned operations for 12 months without additional capital. The pre-funded warrants include beneficial ownership limits of 4.99% (or 9.99% at holder election) and will not be listed, limiting their liquidity.
DarioHealth Corp. reported that the temporary medical leave of absence of its President and Chief Commercial Officer, Steven Nelson, was extended on July 10, 2026 for an indefinite period. During his leave, the company states that his responsibilities are being handled by members of the senior management team.
DarioHealth Corp. reported a first-quarter 2026 net loss of $8.2M, narrowing from $9.2M a year earlier, as operating expenses declined. Revenue fell 17.3% to $5.6M, mainly due to non-recurring pharma revenue in 2025, partly offset by stronger channel partner and direct-to-consumer sales.
Gross margin stayed broadly stable at about 57%, but the company used $6.0M of cash in operations and ended the quarter with $15.0M in cash and $5.0M in short-term deposits. Management disclosed “substantial doubt” about its ability to continue as a going concern over the next 12 months without additional capital or improved performance.
DarioHealth Corp. director John R. Palumbo has filed an initial Form 3 stating beneficial ownership of 4,500 shares of DarioHealth common stock held directly. This filing reports his starting equity position as a director and does not reflect any recent share purchases or sales.
DarioHealth Corp. has appointed veteran healthcare executive John R. Palumbo to its Board of Directors, effective April 10, 2026. Palumbo, age 75, has more than four decades of operating experience across early-stage ventures and large healthcare companies, including leadership roles at AmerisourceBergen, Allscripts and Shared Medical Systems.
He has guided organizations through transformative growth, including supporting two IPOs and major operational and commercial transformations, and currently serves on several healthcare and digital health boards. Dario expects his deep relationships with health systems, payers and senior healthcare executives to support its next phase of partner-led commercial scaling and expansion across payer, provider and health services markets.